Eledon Pharmaceuticals Inc.

2026 Annual Meeting

Investor Materials

Annual Report

View an enhanced version of our Annual Report.

View Document

Proxy Statement

View an enhanced version of our Proxy Statement.

View Document

Request Materials

You may request paper copies of the annual materials online now, by email or by phone by dialing
866-648-8133.

Online Email

Voting

Your vote is Important!

Please be sure to vote your shares online now or vote by phone by dialing 866-229-2195.

Vote Now

Annual Meeting

Date:
June 18, 2026

Time:
11:30 AM PT

Location:
Eledon Pharmaceuticals
19800 MacArthur Blvd., Suite 250
Irvine, California 92612

About Us

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (“ALS”). The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential.

Learn More